



isw2024.org

# **Pregnancy-associated Breast Cancer: Impact of Pregnancy on Surgical Adherence**

<u>Mao Li Cheng<sup>1\*</sup></u>, Visalini Sanmugachandran<sup>1</sup>, Yee Ling Tan<sup>1</sup> Sadhana Mahamad<sup>1</sup>, Anita Baghawi<sup>1</sup>,

Abdullah Nor Hisham<sup>1</sup>

<sup>1</sup>Department of Surgery, Hospital Putrajaya

## Introduction

The incidence of pregnancy-associated breast cancer (PABC) has been in an increasing trend because modern women delay childbearing into their third and fourth decade. Even breast cancer therapies have been progressively advancing to improve survival, PABC women have higher risk of death and recurrence. Therefore, the treatment adherence is crucial for the optimal outcome.

## **Materials and Methods**

All newly diagnosed breast cancer from January 1, 2013, to Sept 30, 2023 were reviewed in this singleinstitution study. PABC is defined as newly diagnosed breast cancer during the antenatal period or in the first postpartum year and the surgical adherence is defined as women undergoing surgery within 30 days of tissue diagnosis or post neoadjuvant chemotherapy.

## Results

Category	Total patients, n (%)	Time to surgery interval (Days)		Median (IQR)	
	ii ( 70)	≤ 30	> 30		
No. Patients, n (%)	30	9 (36.0%)	16 (64.0)	79.0 (36.0, 159.0)	
Breast-conserving surgery	3 (10.0)	0	3 (100.0)	117.3 (33.5)*	
Mastectomy	22 (73.3)	9 (40.9)	13 (59.1)	57.0 (28.8,164.3)	
Reconstruction	3 (13.6)	3 (100.0)	0	124.3 (89.7)*	
No reconstruction	19 (86.4)	13 (68.4)	6 (31.6)	52.0 (29.0, 156.0)	
No surgery	5 (16.7)	-	-	-	
*Moon (CD)					

\*Mean (SD)


## **Table 1 Time to Surgery Interval**

Category	Frequency (%)	
	n = 30	

Category	Frequency (%) n = 30		
Tumour size (mm) (Median, IQR)	4.8 (3.0,7.0)		
Tumour histology			
IDC	28 (93.3)		
ILC	0		
DCIS	1 (3.3)		
Others	1 (3.3)		
Grading			
1	1 (3.3)		
2	12 (40.0)		
3	12 (40.0)		
NA	5 (16.7)		
Lymphovascular invasion (LVI)			
Yes	13 (43.3)		
Νο			
NA	11 (43.3)		
Molecular classification			
Luminal A	10 (33 3)		

Malay    28 (93.3)      Chinese    2 (6.7)      Indian    0      Others    0      Gestation week    17.4 (9.5)      First trimester    11 (36.7)      Second trimester    11 (36.7)      Third trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    7      Yes    11 (36.6)      No    19 (63.3)      Comorbidity    24 (80.0)      Financial reimbursement    7      Yes    14 (46.7)      No    16 (53.3)      Presenting symptom    30 (100.0)      Non-breast lump    0      Duration of symptom (months)    7 (9.8)	Age (Year) (Mean, SD)	34.2 (4.8)	
Chinese    2 (6.7)      Indian    0      Others    0      Gestation week    17.4 (9.5)      First trimester    11 (36.7)      Second trimester    11 (36.7)      Second trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Yes    11 (36.6)      No    19 (63.3)      Comorbidity	Ethnicity		
Indian    0      Others    0      Gestation week    17.4 (9.5)      First trimester    11 (36.7)      Second trimester    11 (36.7)      Second trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Family history of breast cancer    11 (36.6)      No    19 (63.3)      Comorbidity	Malay		
Others    0      Gestation week    17.4 (9.5)      First trimester    11 (36.7)      Second trimester    11 (36.7)      Third trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Family history of breast cancer    11 (36.6)      No    19 (63.3)      Comorbidity    4 (80.0)      Financial reimbursement    14 (46.7)      Yes    14 (46.7)      No    16 (53.3)      Presenting symptom    30 (100.0)      Breast lump    30 (100.0)      Non-breast lump    0      Duration of symptom (months)    7 (9.8)	Chinese	2 (6.7)	
Gestation week    17.4 (9.5)      First trimester    11 (36.7)      Second trimester    11 (36.7)      Third trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Family history of breast cancer    11 (36.6)      Yes    11 (36.6)      No    19 (63.3)      Comorbidity    2      Yes    6 (20.0)      No    24 (80.0)      Financial reimbursement    14 (46.7)      Yes    14 (46.7)      No    16 (53.3)      Presenting symptom    0      Breast lump    00 (100.0)      Non-breast lump    0      Duration of symptom (months)    7 (9.8)	Indian	0	
First trimester    11 (36.7)      Second trimester    11 (36.7)      Third trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Yes    11 (36.6)      No    19 (63.3)      Comorbidity    6 (20.0)      No    24 (80.0)      Financial reimbursement    14 (46.7)      Yes    14 (46.7)      No    16 (53.3)      Presenting symptom    30 (100.0)      Non-breast lump    0      Duration of symptom (months)    7 (9.8)	Others		
Second trimester    11 (36.7)      Third trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Yes    11 (36.6)    3 (10.0)      Comorbidity    19 (63.3)    3      Comorbidity    6 (20.0)    3    3      Financial reimbursement    24 (80.0)    3    3      Financial reimbursement    30 (100.0)    30 (100.0)    30 (100.0)    30 (100.0)      Breast lump    30 (100.0)    30 (100.0	Gestation week	17.4 (9.5)	
Third trimester    5 (16.7)      Postpartum    3 (10.0)      Family history of breast cancer    3 (10.0)      Yes    11 (36.6)      No    19 (63.3)      Comorbidity    6 (20.0)      No    24 (80.0)      Financial reimbursement    74 (46.7)      No    16 (53.3)      Presenting symptom    30 (100.0)      Non-breast lump    0      Duration of symptom (months)    7 (9.8)			
Postpartum3 (10.0)Family history of breast cancerYesYes11 (36.6)No19 (63.3)ComorbidityYesYes6 (20.0)No24 (80.0)Financial reimbursementYesYes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)			
Family history of breast cancer  11 (36.6)    Yes  11 (36.6)    No  19 (63.3)    Comorbidity			
Yes    11 (36.6)      No    19 (63.3)      Comorbidity			3 (10.0)
No19 (63.3)ComorbidityYes6 (20.0)No24 (80.0)Financial reimbursementYes14 (46.7)No16 (53.3)Presenting symptomBreast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)			
Yes6 (20.0)No24 (80.0)Financial reimbursement14 (46.7)Yes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	Yes		
Yes6 (20.0)No24 (80.0)Financial reimbursement14 (46.7)Yes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)		19 (63.3)	
No24 (80.0)Financial reimbursementYes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	-		
Financial reimbursementYes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)			
Yes14 (46.7)No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)		24 (80.0)	
No16 (53.3)Presenting symptom30 (100.0)Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	Financial reimbursement		
Presenting symptomBreast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)	Yes	14 (46.7)	
Breast lump30 (100.0)Non-breast lump0Duration of symptom (months)7 (9.8)		16 (53.3)	
Non-breast lump0Duration of symptom (months)7 (9.8)	Presenting symptom		
Duration of symptom (months) 7 (9.8)	Breast lump	30 (100.0)	
	Non-breast lump	0	
	Duration of symptom (months)	7 (9.8)	
	≤ 3		16 (53.3)
> 3 14 (46.7)	> 3		14 (46.7)

#### **Table 2 Clinical Characteristics**



## Discussion

This study demonstrated low surgical adherence rate, late-stage presentation and high defaulter rate in PABC. This is likely due to the young women commitment to their families and careers. The family history of breast cancer was associated with surgical adherence. This implied breast cancer awareness improved surgical adherence. However, this is a single center study, which has a comprehensive breast service. To our knowledge, this is the first research on surgical adherence among PABC women.

## Conclusion

Breast cancer awareness and treatment counselling are crucial to improve the breast health literacy among PABC women. Hence, better breast health literacy, better surgical adherence.

#### Luminai A 10 (33.3) Luminal B 8 (26.7) HER-2 4 (13.3) **Triple negative** 8 (26.7)

## **Table 3 Pathological Characteristics**

Category	Frequency (%) n = 24			
Mode of delivery				
Spontaneous vaginal birth	7 (29.2)			
Caesarean section	17 (70.8)			
Prelabour		12 (50.0)		
Intrapartum		5 (20.8)		
Duration of Pregnancy				
Preterm	11 (45.8)			
Term (≥37 weeks)	13 (54.2)			
Maternal morbidity				
Yes	0			
No	24 (100.0)			
Perinatal death				
Yes	0			
No	24 (100.0)			
Birthweight percentiles				
<10 <sup>th</sup>	9 (37.5)			
10 <sup>th</sup> – 90 <sup>th</sup>	14 (58.3)			
>90 <sup>th</sup>	1 (4.2)			

### **Table 3 Maternal and Perinatal Outcomes**

Category	Adherence (%)	Crude odds ratio	95% CI	Adjusted odds ratio*	95% CI
Family history of breast cancer					
No	3 (33.3)		Refe	rence	
Yes	6 (66.7)	8.7	1.3, 56.2	11.5	1.0, 127.8

\*Multiple logistic regression - adjusted for age, ethnicity, gestation week, family history, comorbidity, financial reimbursement, duration of symptoms, and tumour size

#### **Table 4 Univariate and Multivariate Analysis of Surgical Adherence**

#### Reference

- Cheng et al. Breast J. 2020 Mar; 26(3): 568-570 1.
- Bleiche et al. JAMAOncol, 2(3):330-339, 2016 2.
  - Srokowski et al. Cancer, 113(1), 22-29, 2008 3.